Get started
Work

Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

Year: 2020
Type: article
DOI: 10.1038/s41391-020-0210-x
Authors: Risa L. Wong, Mai T. Duong, Catherine M. Tangen, Neeraj Agarwal, Heather H. Cheng, Nicholas J. Vogelzang, Maha Hussain, Ian M. Thompson, David I. Quinn, Evan Y. Yu
Institutions: University of Washington, Fred Hutch Cancer Center, Huntsman Cancer Institute, Northwestern University, Christus Santa Rosa Health System, University of Southern California, USC Norris Comprehensive Cancer Center
Language: English
Field: Medicine
Open Access status: green
Awards: G1347238333, G1548551769, G1938688226, G2002724969, G2057923966, G2276667821, G2345882982, G2509465741, G2750730928, GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM, UCDCCC NCTN U10 Program, Southeast Cancer Control Consortium, Inc, G3484997517, City of Hope Southwest Oncology Group Clinical Trials, G3647597407, G3737421695, SWOG Network Group Operations Center of the NCTN, G3939550896, G4017138494, Southwest Oncology Group, G4706691921, G4768276527, G5187432406, G5448779787, G5543259819, NCI NCTN- Network Lead Academic Participating Site: USC, G6211207823, G7230571265, CENTRAL ILLINOIS COMMUNITY CLINICAL ONCOLOGY PROGRAM, Nevada Cancer Research foundation-Community Clinical Oncology Program, G7860541851, G8006406963, G8231620523, G8413228103, SOUTHWEST ONCOLOGY GROUP, G8777682367, G8898045420
OpenAlex ID: W3005759760
FWCI: 0.738
Cites: 24
Cited by: 12
Related to: 10